eligibility_summary
Inclusion: Adults ≥18 with newly diagnosed Ph+ (t(9,22)/BCR‑ABL/FISH+) ALL, CD19+ blasts, expected survival >3 mo, adequate organs (bili ≤1.5×ULN, ALT/AST ≤2.5×ULN or ≤5× if liver involvement, creat ≤1.5×ULN, amylase/lipase ≤1.5×ULN, alk phos ≤2.5×ULN unless tumor, K/Mg/Phos ≥LLN, LVEF ≥45%), consent. Exclusion: CML blast crisis, prior anti‑ALL therapy, major cardiac disease/MI <12 mo, uncontrolled infection, HIV, pancreatitis, TG>450, other malignancy <5 yrs/residual (except excised in situ/non‑melanoma skin), pregnancy/breastfeeding, active CNS/extramedullary ALL, HbA1c >7.5%, serious psychiatric illness, other unsuitable conditions.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Single‑arm study in newly diagnosed adult Ph+ B‑ALL using frontline targeted therapy plus low‑intensity chemo, followed by CD19 CAR‑T consolidation. Interventions and mechanisms: 1) Olverembatinib — small‑molecule BCR‑ABL tyrosine kinase inhibitor (TKI) to suppress BCR‑ABL signaling driving Ph+ ALL. 2) Venetoclax — oral small‑molecule BCL‑2 inhibitor to restore mitochondrial apoptosis in leukemic blasts. 3) Reduced‑intensity cytotoxic chemotherapy — debulking/induction. 4) CD19 CAR‑T cells — murine‑derived, second‑generation CAR with 4‑1BB costimulation (single infusion, 1×10^6 CAR+ cells/kg) for targeted killing and T‑cell persistence. Targeted cells/pathways: CD19+ B‑ALL blasts, BCR‑ABL kinase pathway, anti‑apoptotic BCL‑2 pathway, T‑cell activation via 4‑1BB.